In this open-label single arm phase 2 study, approximately 20 patients with MF demonstrating suboptimal response to ruxolitinib monotherapy will be enrolled. Patients will continue to receive ruxolitinib at a stable dose and ropeginterferon alfa 2b will be added to the regimen.
Willing and able to provide informed consent
Age ≥18 years
Diagnosis of Overt Myelofibrosis (primary, post-ET, or post-PV) per World Health Organization (WHO) 2022 diagnostic criteria
Intermediate-1, Intermediate-2, or high-risk disease by Dynamic International Prognostic Scoring System (DIPSS)
Prior or current use of interferon alfa (IFNα) preparations for MPN
Patients currently on other investigational therapy (ies)
Contraindications or hypersensitivity to IFNα preparations
History of organ and haematopoietic stem cell transplantation